Afeyan warns U.S. science backlash could slow biotech innovation
Investor Noubar Afeyan warns in his annual letter that a domestic backlash against science and policy cuts could slow biomedical advances, threaten life expectancy, and widen the gap with China, a message delivered at the JPMorgan Healthcare Conference.